Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Voir plus

 

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Voir plus

April 19, 2021

Interview of Stanislas Veillet, CEO of Biophytis on La Bourse ou la Vide.com (in French).

Watch the Video

APRIL 7, 2021

Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma.  You can see the interview here

Our science

Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative and metabolic stresses that lead to age-related diseases.

See more

Pipeline

Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD. Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry AMD and Stargardt disease.

See more

Investors

BIOPHYTIS ON THE STOCK MARKET

Biophytis has been listed on the market Euronext Growth Paris
since July 13, 2015.

ISIN : FR0012816825
Ticker: ALBPS
Type of listing : continuous
Number of outstanding shares: 113 160 071  (as of April 1st, 2021)
Eligible for PEA and PEA-PME equity saving plans

Click here for live stock price

See more